SIMCERE PHARMA (02096) saw its shares rise nearly 8% before the midday break. At the time of writing, the stock was up 7.87%, trading at HK$12.06, with a turnover of HK$45.592 million. On March 25, the company announced that Zhou Yunshu, the former Chairman of HENGRUI PHARMA, has officially joined SIMCERE PHARMA as Chief Executive Officer. The company spoke highly of Zhou's appointment, noting his extensive experience in managing domestic pharmaceutical enterprises. His tenure at HENGRUI PHARMA, where he drove the company's transition toward innovative drug development, was highlighted as evidence of his expertise and practical experience in both R&D and commercialization of novel therapeutics. SIMCERE PHARMA's recently released annual results showed total revenue of RMB 7.731 billion for the full year, a year-on-year increase of 16.5%. Revenue from innovative drugs reached RMB 6.304 billion, up 27.9% compared to the previous year. Net profit attributable to shareholders was RMB 1.344 billion, surging 86.2% year-on-year. Notably, innovative drugs now account for 81.5% of total revenue, a record high. Currently, SIMCERE PHARMA has ten innovative drugs on the market, with more than five additional candidates nearing approval, expected to be launched between 2026 and 2028, laying the foundation for sustained future growth.
Comments